Clinical trials: Botulinum toxin type A
Plantar Fasciitis
DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.
- Trial name
- NCT02973269
- Testing
- daxibotulinumtoxin type A
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Revance Therapeutics, Inc.
Skin Aging
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
This is a safety and efficacy study of botulinum toxin type A in subjects with lateral canthal lines.
- Trial name
- REALISE 1 (NCT02580370)
- Testing
- Botulinum toxin type A
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
The Treatment of Glabellar Frown Lines
The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).
- Trial name
- NCT02096081
- Testing
- IncobotulinumtoxinA, OnabotulinumtoxinA
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Merz North America, Inc.
Moderate to Severe Glabellar Lines
A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety,immunogenicity and efficacy of YY001 for the treatment of moderate to severe glabellar lines in male…
- Trial name
- NCT05743634
- Testing
- YY001, OnabotulinumtoxinA
- Where
- 6 sites in China
- Volunteers
- 140 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Cerebrovascular Accident, Muscle Spasticity
Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm
The main purpose of this study is to assess the effect on Quality of Life of two cycles of Dysport treatment on post-stroke spasticity of the upper limb. The effect of treatment on spasticity and function will also be measured.
- Trial name
- NCT00216411
- Testing
- Botulinum toxin type A
- Where
- 6 sites in Australia
- Volunteers
- 96 people
- Sponsor
- Ipsen
Cervical Dystonia
Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia
Study is to investigate the use of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scale in a cervical dystonia population treated with botulinum toxin type A, and placebo.
- Trial name
- NCT00564681
- Testing
- botulinum toxin type A, botulinum toxin type A Formulation 2, Normal Saline
- Where
- 16 sites in United States, Canada and 14 more
- Volunteers
- 242 people
- Sponsor
- Allergan
Spasmodic Torticollis
Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia
The purpose of this study is to compare two types of botulinum toxin type A to treat the involuntary muscle contractions in the neck
- Trial name
- NCT00432341
- Testing
- botulinum toxin type A
- Where
- 3 sites in Argentina, Australia and 1 more
- Volunteers
- 54 people
- Sponsor
- Allergan
Pediatrics, Muscle Spasticity
BOTOX® Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603602
- Testing
- botulinum toxin Type A
- Where
- 45 sites in United States, Canada and 7 more
- Volunteers
- 235 people
- Sponsor
- Allergan
Forehead Lines
A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines
Facial lines that develop from repeated facial expression, such as forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05152576
- Testing
- OnabotulinumtoxinA X
- Where
- 8 sites in United States
- Volunteers
- 124 people
- Sponsor
- Allergan
Hyperhidrosis
GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis
The primary objective of this study is to demonstrate superiority of single treatment of GSK1358820 (hereinafter, referred to as BOTOX®) over placebo in terms of the efficacy of treatment with BOTOX® 50 U in each axilla (100 U in…
- Trial name
- NCT01128738
- Testing
- GSK1358820
- Where
- 14 sites in Japan
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
- Trial name
- READY-3 (NCT04247074)
- Testing
- botulinum toxin neuromodulator
- Where
- 12 sites in United States, Canada
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Sleep-Disordered Breathing
Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders
This proof-of-concept study is to assess the potential benefit of botulinum toxin for patients with sleep-related breathing disorders.
- Trial name
- Snoring (NCT00773591)
- Testing
- NT 201, a Botulinum neurotoxin type A, free of complexing proteins
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Lines
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
This study aims to look at patient and physician satisfaction of long term Glabellar lines (GL) treatment with Dysport in a real life setting.
- Trial name
- APPEAL (NCT02353897)
- Where
- 14 sites in Australia, Brazil and 6 more
- Volunteers
- 150 people
- Sponsor
- Ipsen
Dystonia, Dystonic Disorder
Meditoxin® Treatment in Patients With Cervical Dystonia
To determine the efficacy and safety of Meditoxin in subjects with cervical dystonia compared with placebo (normal saline)
- Trial name
- NCT03232320
- Testing
- Meditoxin
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Medy-Tox
Overactive Bladder
Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder
To investigate the safety of MEDITOXIN in female subjects with idiopathic overactive bladder compared with BOTOX
- Trial name
- NCT03371342
- Testing
- Meditoxin, Botox
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Medy-Tox
Blepharospasm
Blepharospasm Short Interval
The objective of this Phase II study is to show that pre-treated patients with BEB with the need of shortened injection intervals achieve an improved and stable quality of life level if they receive repeated NT 201 injections at…
- Trial name
- NCT00507637
- Testing
- NT 201
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Merz Pharmaceuticals GmbH
Upper Limb Spasticity
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to…
- Trial name
- DIRECTION (NCT04936542)
- Testing
- AboBoNT-A, OnaBoNT-A
- Where
- 76 sites in United States, Canada and 2 more
- Volunteers
- 464 people
- Sponsor
- Ipsen
Healthy
Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers
To determine the pharmacodynamic and safety of MBA-P01 in Healthy Male Volunteers
- Trial name
- NCT03547141
- Testing
- MBA-P01, BOTOX
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Medy-Tox
Cervical Dystonia
Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Open label study to evaluate the safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in adult patients with a clinical diagnosis of Cervical Dystonia (CD).
- Trial name
- NCT00702754
- Testing
- Botulinum Toxin Type B
- Volunteers
- 502 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Episodic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine.
- Trial name
- E-BEOND (NCT06047457)
- Testing
- Botulinum toxin type A
- Where
- 105 sites in United States, Canada and 6 more
- Volunteers
- 751 people
- Sponsor
- Ipsen